Prevention of skeletal related events and treatment of giant cell tumour of bone
PROLIA — AMGEN, approved 2026-06-23 (BLA125320).
134,272 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.